FINWIRES · TerminalFinancial News · Live TerminalLIVE

HKG:1177

20 stories mentioning HKG:1177Updated 3d ago

Every FINWIRES story that references HKG:1177, newest first.

Sino Biopharma Forms Indonesia Joint Venture with Tempo Scan

Sino Biopharmaceutical (HKG:1177) formed an Indonesian joint venture with Tempo Scan Pacific to commercialize pharmaceutical products in Indonesia.The venture, Tempo CTTQ Biopharmaceutical Indonesia, is 51%-owned by Sino Biopharma and 49%-owned by Tempo Scan, according to a Monday Hong Kong bourse filing.The JV will focus on regulatory affairs, clinical trials, market entry and commercialization of pharmaceutical products, while evaluating opportunities for manufacturing in Indonesia in the future.Several products have already obtained regulatory approval or are under regulatory review.

Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$8.26 From HK$8.67, Keeps at Buy

Sino Biopharmaceutical (HKG:1177) has an average rating of buy and mean price target of HK$7.97, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Sino Biopharma Unit Gets Trial Approval for Chronic Hepatitis B Drug in China

Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical obtained clinical trial approval for the IM-101 injection from China's National Medical Products Administration.The drug candidate has been developed for the treatment of chronic hepatitis B, according to a Thursday Hong Kong bourse filing.

Sino Biopharma Unit Gets Breakthrough Therapy Designation for Neuropathic Pain Drug in China

Sino Biopharmaceutical (HKG:1177) unit Beijing Tide Pharmaceutical's TRD205 obtained breakthrough therapy designation from China's National Medical Products Administration.The move came following positive results from a phase II clinical trial of the drug for chronic post-surgical neuropathic pain, according to a Tuesday Hong Kong bourse filing.

Sino Biopharma Unit Gets China Acceptance for Biliary Tract Cancer Drug

Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group got acceptance for the TQB3454 tablet from China's National Medical Products Administration.The acceptance is for use of the drug to treat advanced biliary tract cancer harboring IDH1 mutations, according to a Friday Hong Kong bourse filing.

Sino Biopharma Unit to Commercialize GSK Respiratory Drugs in Mainland China

Sino Biopharmaceutical (HKG:1177) said subsidiary Chia Tai Tianqing Pharmaceutical expanded its collaboration with GlaxoSmithKline to commercialize two respiratory products in mainland China.Chia Tai Tianqing will obtain commercialization rights for GSK's Trelegy Ellipta and Anoro Ellipta in mainland China and will handle importation, distribution, hospital access and promotional activities for the products, according to a Hong Kong bourse filing on Wednesday.The products are combination inhalation therapies used in the treatment of respiratory conditions.

Sino Biopharma Unit's Application for Analgesic Accepted in China

Sino Biopharmaceutical (HKG:1177) unit Beijing Tide Pharmaceutical's new drug application for ropivacaine hydrochloride sustained-release solution was accepted by China's National Medical Products Administration.The acceptance is for the drug as a postoperative long-acting analgesic in adults, according to a Friday Hong Kong bourse filing.

Sino Biopharmaceutical Unit Gets Marketing Nod for Wound Treatment Drug in China

Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group obtained marketing approval for the Peceleganan Spray, according to a Tuesday Hong Kong bourse filing.The drug was developed under an exclusive partnership by Chia Tai Tianqing Pharmaceutical.The approval is for the treatment of wound infections secondary to first-degree or superficial second-degree burns and scalds caused by Staphylococcus epidermidis, Staphylococcus haemolyticus and Acinetobacter baumannii.

Sino Biopharmaceutical Unit's Application for Gastric Cancer Drug Accepted in China

Sino Biopharmaceutical (HKG:1177) unit LaNova Medicines' new drug application for tecotabart vedotin was accepted by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The product is intended for the treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Sino Biopharmaceutical Plans HK$2 Billion Stock Buyback

Sino Biopharmaceutical (HKG:1177) has approved a plan to spend up to HK$2 billion over the next 12 months on share repurchases in the open market, according to a filing with the Hong Kong Exchange on Monday.The approved amount may be used for shares repurchased directly by the biotech firm as well as shares acquired by the trustee administering its restricted share award scheme.Since the start of 2026, the company has spent about HK$338 million to acquire 60.35 million shares under its repurchase program.

Sino Biopharma Unit Gets Marketing Nod for Licensed Opioid-Induced Constipation Drug in China

Sino Biopharmaceutical (HKG:1177) said Naldemedine obtained marketing approved from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The drug, which has been exclusively licensed by unit Chia Tai Tianqing Pharmaceutical Group, got the approval for the treatment of opioid-induced constipation in adults.

Sino Biopharma Unit's Biliary Tract Cancer Drug Gets Priority Review Status in China

Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's TQB3454 tablet was included in the priority review list by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The drug is indicated for the treatment of patients with locally advanced, recurrent and/or metastatic biliary tract cancer harboring IDH1 mutations.

Asia Markets80d ago

Hong Kong Stocks Little Changed as U.S.-Iran Talks Remain Deadlocked; LDROBOT Gains on Debut

Hong Kong stocks were broadly unchanged Monday as diplomatic tensions between the U.S. and Iran remained unresolved.The Hang Seng Index rose 13.13 points to end little changed at 26,406.84, while the Hang Seng China Enterprises Index barely moved in negative territory, slipping 4.87 points to finish at 8,884.20.U.S. President Donald Trump on Sunday rejected Iran's response to a U.S. proposal aimed at ending the conflict, calling Tehran's demands "totally unacceptable."Iran's proposal centered on ending the conflict, lifting sanctions, securing reparations, and gaining recognition of its control over the Strait.Meanwhile, Trump and Chinese President Xi Jinping are expected to discuss Iran, Taiwan, artificial intelligence, and nuclear weapons as the two sides consider extending a critical minerals agreement during their first face-to-face meeting in more than six months.Trump is expected to arrive in Beijing on Wednesday ahead of talks scheduled for Thursday and Friday.In corporate news, Shenzhen LDROBOT (HKG:1236) debuted in Hong Kong, closing nearly 128% higher at HK$60.00, compared with the offer price of HK$26.36.Sino Biopharmaceutical (HKG:1177) advanced over 4% after securing rights to supply GlaxoSmithKline's hepatitis B drug bepirovirsen in China.

Hang SengHKG:1177HKG:1236

Update: Wuhan YZY Biopharma, Sino Biopharm Unit's Application for Ascites Drug Accepted in China

(Updated to include Wuhan YZY Biopharma, the drug's primary developer)A new drug application for Wuhan YZY Biopharma's (HKG:2496) M701, a drug co-developed by a unit of Sino Biopharmaceutical (HKG:1177), was accepted by China's National Medical Products Administration.The drug was developed for the treatment of malignant ascites caused by advanced epithelial malignancies, according to two separate filings posted with the Hong Kong bourse Thursday.Chia Tai Tianqing Pharmaceutical Group, Sino Biopharmaceutical's unit had, in August 2024, obtained an exclusive sub-licensable license to register, develop, produce, and commercialize the drug in Mainland China.

HKG:1177HKG:2496

Sino Biopharm Unit's Application for Ascites Drug Accepted in China

Sino Biopharmaceutical (HKG:1177) unit's new drug application for M701 was accepted by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The drug was jointly developed by Chia Tai Tianqing Pharmaceutical Group, a subsidiary of the firm, for the treatment of malignant ascites caused by advanced epithelial malignancies.

Sino Biopharmaceutical Enrolls First Patient in Cafelkibart Cancer Drug Trial

Sino Biopharmaceutical (HKG:1177) enrolled the first patient in the phase 3 clinical trial of cafelkibart to treat gastric cancer, the firm said in a Hong Kong bourse filing Thursday.The company will study the medicine's effectiveness in treating gastric cancer or gastroesophageal junction adenocarcinoma as a second-line treatment.Cafelkibart is also known as LM-108 and was developed by the company's LaNova Medicines unit.

Sino Biopharmaceutical's Breast Cancer Drug Gets Marketing Nod in China

Sino Biopharmaceutical's (HKG:1177) culmerciclib capsule "CDK2/4/6 inhibitor" in combination with fulvestrant obtained marketing approval from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The approval is for use of the drug for initial endocrine therapy for patients with locally advanced or metastatic breast cancer.This is the second indication of the drug approved for marketing.

Sino Biopharmaceutical Appoints Chief Medical Officer

Sino Biopharmaceutical (HKG:1177) appointed Kang Xiaoyan as its chief medical officer, according to a Hong Kong bourse filing Tuesday.Kang has over twenty five years of experience in clinical practice and drug research and development, Sino Biopharmaceutical said.

Sino Biopharmaceutical Unit Gets China Nod to Market Cancer Drug

Sino Biopharmaceutical (HKG:1177) said Benmelstobart in combination with Anlotinib obtained marketing approval from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The approval is for the treatment of advanced or unresectable alveolar soft part sarcoma.Benmelstobart and Anlotinib are category 1 innovative drugs developed by Chia Tai Tianqing Pharmaceutical Group, a unit of the company.

Sino Biopharmaceutical Unit Enrolls First Patient in Gastric Cancer Drug Trial

Sino Biopharmaceutical (HKG:1177) said unit LaNova Medicines' phase III registrational clinical trial of tecotabart vedotin completed the enrollment of the first patient, according to a Wednesday Hong Kong bourse filing.The study is testing the drug for the first-line treatment of gastric and gastroesophageal junction adenocarcinoma in combination with a PD-1 monoclonal antibody.

Track with the FINWIRES app suite

Track HKG:1177 in your portfolio

Analyze HKG:1177 options with the wheel strategy

See market sentiment on HKG:1177